FAQs Sign up for updates

Want to know the latest on AUM's products?

Sign up today to get the most exclusive discounts offers
 
 
   
FANA vs shRNA

AUMlnc oligos

FANA antisense oligos (FANA ASOs) for lncRNA silencing and regulation

AUMlnc oligos provide potent lncRNA knockdown by using FANA technology which is a third generation chemical modification platform. FANA technology allows simple and efficient delivery into difficult-to-transfect cells and animals without the need of transfection reagents or formulations.

AUMlnc : Key features

  • Easy self-delivery without the need of transfection regents

  • Excellent uptake in difficult-totransfect cells and primary cultures

  • No toxicity

  • High specificity and affinity for target lncRNA

  • High stability and resistance to endonucleases

FANA ASOs vs. siRNA
Not Required Transfection Reagents Required
High Efficiency in difficult-to-transfet cells Low-Moderate
Non-toxic Toxicity Can be toxic due to the use of transfection reagents
Easy and convenient one-step process Transition from cell culture to in vivo models Require extensie optimization use of delivery reagents
High: Resistant to nucleases Stability Moderate
No RISC-associated off-target effects Yes
FANAs have high binding affinity and specificity to the target RNA Specificity siRNA grade binding affinity and specificity

Lipid-based transfection and electroporation are widely utilized, conventional methods to deliver siRNA into the cells. However, in many primary cells, particularly immune cells, hematopoietic cells and neurons, lipid reagents and electroporation are associated with high toxicity and poor transfection efficiency. Alternative delivery methods, such as viral vectors, require laborious optimization and viral production steps, and carry associated risk of genome integration.

FANA Antisense Oligonucleotides (FANA ASOs) are uniquely modified with 2'-deoxy-2'-fluoro-arabinoguanosine (FANA) that enhances the intracellular stability of the oligos, as well as their binding to the target lncRNA. The FANA modifications also allow for the oligos to be self-delivered into cells without any transfection reagents, as well as in animals, without the need of special delivery formulations.

Comparison of FANA ASO and siRNA mode of action

As opposed to the RNAi pathway (involving RISC) FANA single-stranded antisense oligonucleotides use RNase H-mediated cleavage (Fig.1). This mode of lncRNA knockdown is simpler than siRNA mediated knockdown and eliminates RISC-associated offtarget effects often observed with siRNA. Unlike siRNAs that are processed in the cytoplasm, FANA oligos can go into the nucleus and can be used to target RNA present within the nucleus. Most importantly FANAs can be self delivered and do not need transfection reagents or delivery agents.

Case Study

Knockdown of yylncT lncRNA by FANA ASO in human embryonic stem cells. FANA ASO mediated depletion of the target transcript led to a significant decrease in early mesoderm markers, suggesting that yylncT is a mediator of the mesoderm fate of human embryonic stem cells. Adapted from Frank et al. Cell Stem Cell.

Ordering information:

Product Name Purification Application Study model
AUMlnc RPC lncRNA knockdown Cells lines and primary cells
AUMlnc HPLC lncRNA knockdown Sensitive primary cells and animal models
AUMlnc In-vivo ready lncRNA knockdown Animal models
Notes:
  • Labeled FANAs: FANA ASOs can be labeled with any fluorescent label or tag (eg. biotin).

  • Size: FANAs are available in 10, 25, 50, 100, 250, 500 and 1000 nmoles. Higher amounts are also available.

To order please visit:
AUMlnc

Or email us at:

customercare@aumbiotech.com
Download PDF